Late life depression is highly prevalent and associated with an increased risk of
morbidity, poor physical and cognitive functioning, and suicide. Yet, standard antidepressants
are often ineffective; thus, many older adults have treatment-resistant depression
(TRD, defined as failure of two oral antidepressants). Few medication options exist
for TRD in older adults, with aripiprazole being one notable exception.
1
Electroconvulsive therapy is often the next step in treatment but is limited in availability
and often associated with short-term memory loss.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of Geriatric PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation.Am J Geriatr Psychiatry. 2016; 24: 918-922https://doi.org/10.1016/j.jagp.2016.04.015
- The efficacy and safety of esketamine for the treatment-resistant depression in older adults: comments on TRANSFORM-3 trial results.Am J Geriatr Psychiatry. 2020; 28: 142-144https://doi.org/10.1016/j.jagp.2019.10.009
- Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry. 2006; 163: 1905-1917https://doi.org/10.1176/ajp.2006.163.11.1905
- Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).Arch Gen Psychiatry. 2006; 63: 1337-1344https://doi.org/10.1001/archpsyc.63.12.1337
- Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.J Clin Psychopharmacol. 2014; 34: 285-286https://doi.org/10.1097/JCP.0000000000000090
- Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.Br J Anaesth. 2018; 121: 1075-1083https://doi.org/10.1016/j.bja.2018.03.030
- Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.Am J Geriatr Psychiatry. 2020; 28: 121-141https://doi.org/10.1016/j.jagp.2019.10.008
- Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression.Am J Geriatr Psychiatry. 2017; 25: 1199-1209https://doi.org/10.1016/j.jagp.2017.06.007
Article info
Publication history
Published online: January 18, 2021
Accepted:
January 12,
2021
Received:
January 9,
2021
Identification
Copyright
© 2021 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.
